header logo image


Page 38«..1020..37383940..5060..»

Archive for the ‘Regenerative Medicine’ Category

International Regenerative Medicine Symposium will officially take place in Rabat, Morocco – PRUnderground (press release)

Saturday, August 19th, 2017

ISSCA 5TH INTERNATIONAL SYMPOSIUM TO TAKE PLACE AT THE HOTEL SOFITEL IN RABAC THIS SEPTEMBER 30

Global Stem Cells Group, a global network of practitioners, doctors, researchers, and medical advocates that work in tandem to advance the study of regenerative medicine and stem cell development in our world today, this week, through their Stem Cell Conference subsidiary branch, officially announced their International Society for Stem Cells Application (ISSCA) 5th International Regenerative Medicine Symposium will officially take place at the Hotel Sofitel in Rabac.

Occurring this September 30, 2017, the symposium stands to bring together the industrys leading thinkers and doctors for days of collaboration.

To complement the hosting of the symposium, Global Stem Cells Group also announced a scientific program with three different modules that will be made available to event attendees.

We are constantly developing new events, programs, and educational opportunities that provide doctors and students with the ability to learn about regenerative medicine in a live and supportive environment, said Dr. Benito Novas, Founder and Owner of Global Stem Cells Group. We are incredibly excited to be hosting our symposium at the Hotel Sofitel, and we look forward to administering our scientific program to all who are interested.

Module 1, Biologic and Molecular basis for Regenerative Medicine, includes cellular culture and expansion, therapeutic potential, bioactive agents, plus much more. Module 2, Therapeutic Applications: Adult Stem Cells from Bench to Bedside, goes through regenerative orthopedics, protocols, and clinical experiences for students. Lastly, Module 3, Regulations, Marketing and Global Overview of the Stem Cell Industry, is a U.S. Research Policy and Stem Cells overview of the FDA regulatory process today.

To learn more about the program, visit http://www.stemcellgroup.org.

To learn more about the event, visit: http://www.stemcellconference.org.

About Global Stem Cells Group

Read more from the original source:
International Regenerative Medicine Symposium will officially take place in Rabat, Morocco - PRUnderground (press release)

Read More...

Collagen & Gelatin Market for Regenerative Medicine (by Source … – PR Newswire (press release)

Saturday, August 19th, 2017

NEW YORK, Aug. 16, 2017 /PRNewswire/ -- "Global collagen & gelatin market for regenerative medicine projected to grow at a CAGR of 10.1% and 7.8% respectively."

The global collagen market for regenerative medicine is projected to grow from USD 420.6 million in 2017 to USD 679.9 million by 2022, at a CAGR of 10.1% during the forecast period.

Read the full report: http://www.reportlinker.com/p05064743/Collagen-Gelatin-Market-for-Regenerative-Medicine-by-Source-Bovine-Porcine-Marine-Application-Wound-Care-Orthopedic-Cardiovascular-Value-and-Volume-Analysis-Global-Forecast-to.html

The global gelatin market for regenerative medicine is projected to grow from USD 65.2 million in 2017 to USD 94.9 million by 2022, at a CAGR of 7.8% during the forecast period. The key factors propelling the growth of the global collagen and gelatin market for regenerative medicine include rising prevalence of chronic diseases, rapid growth in aging population, and growing government & private funding to support the development of regenerative medicine. However, the availability of alternative biomaterials for regenerative medicine is expected to restrain the growth of this market.

"The marine collagen segment is expected to grow at the highest CAGR in the global collagen market for regenerative medicine." On the basis of source, the global collagen market for regenerative medicine has been classified into bovine collagen, porcine collagen, marine collagen, and other sources. In 2017, the bovine collagen segment is expected to command the largest share of the global collagen market for regenerative medicine. However, owing to advantages, such as low immunogenicity and high biocompatibility the marine collagen segment is projected to grow at the highest CAGR during the forecast period.

"The orthopedic segment is expected to grow at the highest CAGR in the global collagen market for regenerative medicine." On the basis of application, the global collagen market for regenerative medicine has been segmented into orthopedic, wound care, cardiovascular, and other applications. In 2017, the orthopedic applications segment is expected to command the largest share of the global collagen market for regenerative medicine. However, owing to factors such as rising prevalence of chronic wounds, the wound care segment is projected to register the highest CAGR during the forecast period.

"Asia-Pacific to witness the highest growth during the forecast period." North America held the largest share of the collagen market for regenerative medicine and gelatin market for regenerative medicine, while Asia-Pacific is expected to witness the highest growth during 2017 to 2022 in both the markets.

The high growth in the collagen market for regenerative medicine can primarily be attributed to the large number of CVD patients and diabetics with DFU (diabetic foot ulcers) in the region, increasing number of research studies, and increasing focus of industry players on emerging APAC countries. Similarly, the large number of patients suffering from skin burns & brain tumors and increasing number of research studies in the region are the major factors driving the growth of the APAC market.

Break of primary participants was as mentioned below: By Company Type Tier 145%, Tier 240% and Tier 315% By Designation C-level41%, Director Level30%, Others29% By Region North America38%, Europe31%, Asia-Pacific19%, RoW12%

The major players operating in the global collagen market for regenerative medicine include Integra LifeSciences Holding Corporation (U.S.), Collagen Matrix, Inc. (U.S.), Collagen Solutions plc (U.K.), Royal DSM (Netherlands), Vornia Biomaterials, Ltd. (Ireland), SYMATESE (France), and NuCollagen, LLC. (U.S.). Similarly, the major players operating in the global gelatin market for regenerative medicine include GELITA AG (Germany), Nitta Gelatin, Inc. (Japan), and PB Gelatin (Belgium).

Research Coverage: The report analyzes the global collagen and gelatin market for regenerative medicine and aims at estimating market size and future growth potential of this market based on various segments such as source, application, and region. The report also includes an in-depth regulatory analysis for various regions across the globe and competitive analysis of the key players in this market along with their company profiles, product offerings, and recent developments.

Reasons to Buy the Report The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned four strategies.

This report provides insights on the following pointers: Market Penetration: Comprehensive information on product portfolios offered by the top players in the global collagen and gelatin market for regenerative medicine. The report analyzes the global collagen and gelatin market for regenerative medicine by source, application, and region Market Development: Comprehensive information about lucrative emerging markets the report analyzes the markets for collagens and gelatins for regenerative medicine across various regions Market Diversification: Exhaustive information about new services or service enhancements, growing geographies, recent developments, and investments in the global collagen and gelatin market for regenerative medicine Competitive Assessment: In-depth assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the global collagen and gelatin market for regenerative medicine

Read the full report: http://www.reportlinker.com/p05064743/Collagen-Gelatin-Market-for-Regenerative-Medicine-by-Source-Bovine-Porcine-Marine-Application-Wound-Care-Orthopedic-Cardiovascular-Value-and-Volume-Analysis-Global-Forecast-to.html

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________Contact Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/collagen--gelatin-market-for-regenerative-medicine-by-source-bovine-porcine-marine-application-wound-care-orthopedic-cardiovascular-value-and-volume-analysis---global-forecast-to-2022-300505537.html

Continued here:
Collagen & Gelatin Market for Regenerative Medicine (by Source ... - PR Newswire (press release)

Read More...

Streetwise Reports Examines One Regenerative Medicine Firm to … – Markets Insider

Saturday, August 19th, 2017

SAN FRANCISCO, CA--(Marketwired - August 18, 2017) - In an update on this company's clinical cell therapy programs targeting blood cancers and osteoarthritis in the knee, Gabrielle Zhou of Maxim Group describes progress that sets the stage for "value inflection."

Included in this article is: Cellular Biomedicine Group Inc.'s(NASDAQ: CBMG)

Zhou summed up Cellular Biomedicine Group Inc.'s recent activities in an Aug. 9 research report. "CBMG's cell therapy programs continue to make progress," she wrote. "We expect to see data from both the CARD-1 and CALL-1 chimeric antigen receptor T-cell (CAR-T) studies by 2017E, setting the stage for a value inflection as CBMG becomes a Phase 2 CAR-T player."

The analyst also noted the company has enough cash to get to that stage. "CBMG ended the period with $27M in cash," Zhou noted. "At the current burn rate, we estimate CBMG has sufficient capital to fund through topline data releases (by 2017E) from its CARD-1 and CALL-1 studies, which should represent catalysts for the stock."

Continue reading this article:'Keep a Close Eye On' This Regenerative Medicine Firm

About Streetwise Reports -- The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

DISCLOSURES:

The following company mentioned in this article is a billboard sponsor of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. Cellular Biomedicine Group Inc. paid Streetwise Reports to distribute this press release on its behalf. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.

Please see the end of the article for the complete disclosures: 'Keep a Close Eye On' This Regenerative Medicine Firm

See more here:
Streetwise Reports Examines One Regenerative Medicine Firm to ... - Markets Insider

Read More...

$774.8 Million Collagen & Gelatin Market for Regenerative Medicine … – PR Newswire (press release)

Saturday, August 19th, 2017

The global collagen market for regenerative medicine is projected to grow from USD 420.6 Million in 2017 to USD 679.9 Million by 2022, at a CAGR of 10.1% during the forecast period.

The global gelatin market for regenerative medicine is projected to grow from USD 65.2 Million in 2017 to USD 94.9 Million by 2022, at a CAGR of 7.8% during the forecast period. The key factors propelling the growth of the global collagen and gelatin market for regenerative medicine include rising prevalence of chronic diseases, rapid growth in aging population, and growing government & private funding to support the development of regenerative medicine.

The report analyzes the global collagen & gelatin market for regenerative medicine by source, application, and region. On the basis of source, the global collagen market for regenerative medicine has been segmented into bovine collagen, porcine collagen, marine collagen, and other sources. In 2017, the bovine collagen segment is expected to command the largest share of the global collagen market for regenerative medicine. The large share of this segment is attributed to the lower cost and extensive availability of bovine collagen.

Similarly, on the basis of source, the global gelatin market for regenerative medicine has been segmented into bovine gelatin, porcine gelatin, and gelatin from other sources. In 2017, the bovine gelatin segment is expected to command the largest share of the global gelatin market for regenerative medicine. Owing to its extensive availability, this segment is also projected to register the highest CAGR during the forecast period.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Collagen Market for Regenerative Medicine, By Source

7 Gelatin Market for Regenerative Medicine, By Source

8 Collagen Market for Regenerative Medicine, By Application

9 Gelatin Market for Regenerative Medicine, By Application

10 Collagen Market for Regenerative Medicine, By Region

11 Gelatin Market for Regenerative Medicine, By Region

12 Competitive Landscape

13 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/jrw4ql/collagen_and

Media Contact:

Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/7748-million-collagen--gelatin-market-for-regenerative-medicine-2017---global-forecast-to-2022-300505917.html

SOURCE Research and Markets

http://www.researchandmarkets.com

The rest is here:
$774.8 Million Collagen & Gelatin Market for Regenerative Medicine ... - PR Newswire (press release)

Read More...

TAT holds global medical tourism event: "Amazing Thailand Health and Wellness Tourism Showcase 2017," focusing … – Markets Insider

Thursday, August 17th, 2017

BANGKOK, Aug. 17, 2017 /PRNewswire/ -- Mr. NoppadonPakprot, Deputy Governorfor Tourism Products and Business,Tourism Authority of Thailand (TAT) presided over the Amazing Thailand Health and Wellness Tourism Showcase 2017 yesterday, which unveiled the latest "Functional & Regenerative Medicine" innovation in Thailand.

Mr. NoppadonPakprot, Deputy Governorfor Tourism Products and Business at TAT said, "Thailand has long been recognized as a world destination for medical tourism. According to a report by VISA and Oxford Economics, Thailand has once more been confirmed as one of Asia's top medical tourism destinations. Thailand now has 58 JCI-accredited hospitals, more than any other Southeast Asian country."

The Amazing Thailand Health and Wellness Tourism Showcase 2017, under the concept "Thailand: a Paradise for Longevity", showcased Thailand as a destination for longevity products and services.

Thailand has adopted the latest innovative medicine of the century: "Functional & Regenerative Medicine," the most popular health trend in the world. In fact, Thailand is the first and only country in Asia that has specialized Functional & Regenerative Medicine hospitals, namely Better Being Hospital and MALI hospital

Moreover, Thailand has become an anti-aging center in Asia with the largest number of American Academy of Anti-Aging Medicine-certified medical professionals in Asia with 500 doctors.

"Recently, the government implemented new medical tourism policies extending the visitor stay period to 90 days for members of CLMV countries andTaiwan in order to accommodate medical tourists traveling to Thailand. In addition, the long-stay visa has also been extended to 10 years for 14 countries as follow: Japan, Australia, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Sweden, Switzerland, UK, Canada and the U.S. These two recent policies should further enhance the positioning of Thailand to be a world-class medical tourism hub recognized the world over."

Mr. Noppadonnoted: "This is the 4th such event that TAT has organized, and this year we proudly present the top 44 Health and Wellness providers in Thailand. This event will display the potential of Thailand along with its plethora of health and wellness products to international awareness. It will also provide a marketing platform for Thai health and wellness providers to discuss prospective business deals with medical tourism facilitators and travel agencies from across the globe."

The one-day event highlighted why Thailand is a "Paradise for Longevity", along with holding an informative presentation on the concept of "Functional & Regenerative Medicine. In the afternoon, buyers had the chance to discuss business deals with the top 44 health and wellness providers in Thailand, including: General Hospital, Plastic Surgery Hospital, Regenerative Functional Medicine Hospital, Anti-Aging Clinic, Cosmetic & Aesthetic Clinic, Dental Clinic, Cell Therapy Clinic, and Lab Check Up, all of whom were ready to discuss prospective business deals with international buyers.

Mr. NoppadonPakprot concluded as follows: "We hope that this event will further strengthen the awareness of Thailand as the premier destination for health and wellness tourism, and that the trade event would help generate more than 500 million Baht to the Thai economy."

Ms. Jittima Udayachalerm, Director, Royal Orchid Plus Business Unit said, "Royal Orchid Plus is delighted to be part of this global medical tourism event at this time. We've created exciting marketing activities to support this project. "We've organized a special event, inviting Royal Orchid Plus Platinum and Gold members to come and get health check-ups for free, and also given them the chance to meet and buy special packages from the hospitals and clinics at the event. Additionally, we will promote an exclusive health and wellness deal to Royal Orchid Plus members through our online channels, including email, social media, and our website."

SOURCE Amazing Thailand Health and Wellness Tourism Showcase 2017

View original post here:
TAT holds global medical tourism event: "Amazing Thailand Health and Wellness Tourism Showcase 2017," focusing ... - Markets Insider

Read More...

Biobanking Market by Product and Service(Equipment, Consumables, Services, Software), Sample Type (Blood … – Markets Insider

Thursday, August 17th, 2017

NEW YORK, Aug. 16, 2017 /PRNewswire/ -- Factors driving the growth of this market include the increasing number of genomics research activities for studying diseases; advances in biobanking and the growing trend of conserving cord blood stem cells of newborns; government & private funding to support regenerative medicine research, and the growing need for cost-effective drug discovery and development. On the other hand, the growth of this market is hindered to some extent due to the high cost of automation and issues related to biospecimen sample procurement.

Read the full report: http://www.reportlinker.com/p05064741/Biobanking-Market-by-Product-and-Service-Equipment-Consumables-Services-Software-Sample-Type-Blood-Products-Human-Tissues-Cell-Lines-Nucleic-Acids-Application-Regenerative-Medicine-Life-Science-Clinical-Research-Global-Forecast-to.html

"Automated storage is expected to register the highest CAGR during the forecast period" The biobanking market is classified by storage type into manual and automated storage. The automated storage type segment is expected to grow at a higher rate during the forecast period. This is attributed to launch of new and advanced automated storage equipment and increasing demand for the quality storage of samples.

"Regenerative medicine to dominate the market during the forecast period"The biobanking market is segmented based on applications regenerative medicine, life science research, and clinical research. In 2017, the regenerative medicine segment is expected to command the largest share and is also estimated to grow at the fastest rate as compared to other segments. This can be attributed to increasing research activities in the field of regenerative medicine and rising demand for well-annotated and quality biosamples for research.

"Asia-Pacific is estimated to grow at the highest CAGR during the forecast period" Geographically, the biobanking market is dominated by North America, followed by Europe. The Asia-Pacific region is estimated to grow at the fastest rate which can be attributed to the large population in China and India, increasing research in regenerative medicine, and improving life sciences research infrastructure in the region.

The primary interviews conducted for this report can be categorized as follows:

The key players in the biobanking market include Thermo Fisher Scientific Inc. (U.S.), Tecan Group Ltd. (Switzerland), Qiagen N.V. (Germany), Hamilton Company (U.S.), Brooks Automation (U.S.), TTP Labtech Ltd (U.K.), VWR Corporation (U.S.), Promega Corporation (U.S.), Worthington Industries [(Taylor Wharton, U.S.)], Chart Industries (U.S.), Becton, Dickinson and Company (U.S.), Merck KGaA (Germany), Micronic (Netherlands), LVL Technologies GmbH & Co. KG (Germany), Panasonic Healthcare Holdings Co. Ltd (Japan), Greiner Bio One [Greiner Holding AG, Austria)], Biokryo GmbH (Germany), Biobank AS (Norway), Biorep Technologies Inc. (U.S.), Cell & Co Bioservices (France), RUCDR infinite biologics (U.S.), Modul-Bio (France), CSols Ltd (U.K.), Ziath (U.K.), and LabVantage Solutions Inc. (U.S.).

Study Coverage:The report analyses the biobanking market by product and service, sample type, storage type, application and regions. Apart from comprehensive geographic & product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by prominent market players to maintain and increase their shares in the market.

Market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output in order to remain successful in the type, products, applications, end users, and regions.

Key benefits of buying the Report:This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies for strengthening their market shares.

The report provides insights on the following pointers:

Read the full report: http://www.reportlinker.com/p05064741/Biobanking-Market-by-Product-and-Service-Equipment-Consumables-Services-Software-Sample-Type-Blood-Products-Human-Tissues-Cell-Lines-Nucleic-Acids-Application-Regenerative-Medicine-Life-Science-Clinical-Research-Global-Forecast-to.html

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

Contact Clare: rel="nofollow">clare@reportlinker.comUS:(339) 368 6001 Intl:+1 339 368 6001

View original content:http://www.prnewswire.com/news-releases/biobanking-market-by-product-and-serviceequipment-consumables-services-software-sample-type-blood-products-human-tissues-cell-lines-nucleic-acids-application-regenerative-medicine-life-science-clinical-research---g-300505662.html

SOURCE Reportlinker

See the rest here:
Biobanking Market by Product and Service(Equipment, Consumables, Services, Software), Sample Type (Blood ... - Markets Insider

Read More...

Editorial: The growth of regenerative medicine – Concord Monitor

Monday, August 14th, 2017

The field is called regenerative medicine, technology that shows promise of repairing or replacing human organs with new ones, healing injuries without surgery and, someday, replacing cartilage lost to osteoarthritis.

New Hampshire could become one of the centers of the new industry and become the next Silicon Valley, says Manchester inventor Dean Kamen. The governor and Legislature, however, arent doing what they need to make the potential economic and intellectual boom more likely.

Sever the spinal chord of a zebra fish, an aquarium standby, and it will regrow in a couple of weeks. Remove a limb from a salamander, and it will grow another one indistinguishable from the first. And even some humans, especially when young, can regrow a new fingertip and fingernail on a digit severed above its last joint. Medical science is moving ever closer to performing such wonders.

3-D bioprinters that use biologic materials instead of printer ink are already printing replacement human skin. A University of Connecticut scientist and surgeon believes it will be possible to regenerate human knees sometime in the next decade and regrow human limbs by 2030.

At Ohio State University, a team has succeeded in using genetic material contained in a tiny microchip attached to skin and, with a tiny, Frankenstein-like zap of electricity, reprogram skin cells to produce other types of human cells. Turn a skin cell into say, a vascular system cell, and it will migrate to the site of a wound, spur healing and restore blood flow. Convert skin cells to brain cells and, with a few more steps, it could help stroke victims recover. The technologys potential is enormous.

Kamen created the portable insulin pump, and he and his team at DEKA Research in Manchesters millyard produced the Segway human transporter, a device that provides clean water in places that lack it, an external combustion engine that will soon heat and power part of the states mental hospital, and other inventions. Their track record helped Kamen and DEKA beat out plenty of other applicants to win $80 million in federal funds to found ARMI, the Advanced Regenerative Manufacturing Institute in Manchester. Total funding is now just shy of $300 million.

The governments aim is to spur technologies that could be used to treat injured soldiers but whats learned could aid everyone and make New Hampshire a mecca for scientists, production facilities, pharmaceutical companies and more. DEKA will not create the new technologies but use its inventing and engineering expertise to help companies scale up and speed up regenerative medicine technologies so they can be brought to the market more quickly at an affordable cost.

The states university system has partnered with DEKA to train students who will one day work in the biotech field. The educational infrastructure is in place, but its handicapped by the states sorry funding of higher education. New Hampshire regularly ranks last or next to last in state support and its students carry the most debt of any in the nation.

To make New Hampshire the biotech mecca Kamen envisions will require lawmakers to better fund higher education, support the regenerative manufacturing institute and make housing available. A high-tech company that wants to come to New Hampshire cant do so if its workers cant afford a home.

Regenerative medicine is expected to become a massive economic engine, one that will create jobs and improve lives while lowering health care costs. The Legislature should be doing all it can to make sure that at least some of that engine is designed and made in New Hampshire.

See the article here:
Editorial: The growth of regenerative medicine - Concord Monitor

Read More...

Editorial: Cell regeneration work a boon to Ohio, health care – Canton Repository

Monday, August 14th, 2017

By The Canton Repository Editorial Board

There's a lot of excitement aboutOhio State University.

That's not unusual at this time of year. After all, the Buckeyes are getting closer to kicking off the 2017 football season.

But, as exciting as their games are each week, what they've got going on pales in comparison to what some researchers are doing at Ohio State's Wexner Medical Center.

In a historic breakthrough, they're helping to save lives, cell by cell. They've successfully turned skin cells into the types of cells the body might need.

What does that mean? The Columbus Dispatch broke it downin a story published last week: "... a technology that has limitless potential, from regenerating a wounded limb to repairing a brain after stroke to healing a damaged heart."

The ramifications are boundless, as is our joy at this breakthrough.

The work started small, building blood vessels to help regenerate limbs in mouse legs within seven to 14 days. Once officials at Walter Reed National Military Medical Center in Bethesda, Md., expressed interest, the work took on a grander scale, the Dispatch reported. The leg-healing process was duplicated in pigs. It's clear the technology can help troops in the field, but researchers reported that it must begin within 72 hours of injury to be successful.

The process seems so simple. Twenty-six researchers in the fields of engineering, science and medicine worked together to develop the technology that involved placing a square chip about the size of a fingernail on the skin, adding a drop containing a genetic code. It then was zapped with an energy source. Researchers told the Dispatchthe genetic material changes depending on the type of regeneration that is needed.

"It's like a syringe that's the chip but then what you load in the syringe is your cargo," Chandan Sen, director of the Center for Regenerative Medicine and Cell-Based Therapies at Wexner Medical Center, told the Dispatch. "Based on what you intend the cells to be, the cargo will change. So, if you want a vasculogenic (blood vessel) cell, the code would be different than if you wanted a neuro cell, and so on and so forth."

The mind reels when you think of the ways in which such technology could be used. Ohio State carefully worked on this project, with funding from private sources because of the high risk of failure, and is preparing to seek approvalfrom the Food and Drug Administration to try it out on humans.

The good news on this project extends to Ohio's economy, because a Columbus company is manufacturing the chips, and it already has drawn interest from a Taiwan-based company. L. James Lee, a professor of chemical and biomolecular engineering at OSU and another of the leading researchers on the project, said the team is looking toprove feasibility within a year.

It's wonderful to see such thoughtful and valuable projects accomplished in Ohio, and for the state to benefit furtherfrom the idea. Ohio is home to a wealth of premier medical institutions, and this is another way the state is shining brightly in a field with tremendous growth potential.

Congratulations to the team at Ohio State. You're champions to us!

Go here to read the rest:
Editorial: Cell regeneration work a boon to Ohio, health care - Canton Repository

Read More...

‘Origami organs’ could be the future of regenerative medicine – New York Post

Thursday, August 10th, 2017

Scientists are making use of discarded animal organs by turning them into origami but its more than just an art project.

A team of researchers at Northwestern University created the paper cranes to demonstrate the flexibility and malleability of their latest breakthrough: a tissue paper that has the potential to heal wounds, prevent scarring and help hormone production in cancer patients.

This new class of biomaterials has potential for tissue engineering and regenerative medicine as well as drug discovery and therapeutics, Ramille Shah, one of the team members, told Northwestern.edu. Its versatile and surgically friendly.

The tissue paper is a blend of proteins from animal organs that, when wet, can be folded, rolled, cut, flattened, balled, ripped and even crafted into tiny birds. It can also be frozen for later use, making it even more practical.

In one of the first lab tests, the team successfully grew hormone-secreting follicles in a culture using a paper made from a cow ovary. Their findings were recently published in Advanced Functional Materials.

And as with many scientific discoveries, the team at Northwestern stumbled upon the new material as an accident.

The scientists were researching 3D-printed mice ovaries when one of the team members spilled the hydrogel-based gelatin ink used in creating the ovaries. The ink pooled into a dry sheet that ended up being surprisingly strong.

The light bulb went on in my head, Adam Jakus, another one of the team members, told Northwestern.edu. I knew right then I could make large amounts of bioactive materials from other organs.

Since then, the researchers have been collecting scrap pig and cow organs from a local butcher and using them to further test out the regenerative tissue paper.

Breaking down everything from animal uteruses to kidneys to muscles to hearts, the team extracts the structural proteins which give an organ its form then dries them out and combines it was a polymer, or resin, which generates the thin, paper structure.

The final product is basically a papier-mch-like sheet of proteins that can retain the biochemicals needed to regenerate a sick or injured piece of tissue, like a human liver, or skin laceration.

Though a lot more research is needed, the material could one day be used to accelerate healing after surgery and help treat hormone deficiencies in cancer patients. The researchers also found it can support human stem cell growth.

It is really amazing that meat and animal by-products like a kidney, liver, heart and uterus can be transformed into paper-like biomaterials that can potentially regenerate and restore function to tissues and organs, Jakus said. Ill never look at a steak or pork tenderloin the same way again.

Read more:
'Origami organs' could be the future of regenerative medicine - New York Post

Read More...

Microchip May Fix Damaged Cells And Organs, Scientists Say … – CBS New York

Thursday, August 10th, 2017

COLUMBUS, Ohio (CBSNewYork) It sounds like something out of a sci-fi novel a microchip that rescues injured or failing organs.

As CBS2s Dr. Max Gomez reported Tuesday, the breakthrough in regenerative medicine is actually being tested right now.

One of the hottest areas of medical research is using cells instead of drugs to treat diseases and injuries. But cellular therapies require finding or making the right type of cells, which can be difficult.

It turns out the body can do it on its own, with a little high-tech help.

The device is only about the size of a cufflink, but what it could represent is enormous. In a laboratory at the Ohio State University Wexner Medical Center, researchers demonstrated how it reprograms cells.

The chip is simply placed on an injured part of the body and a small electrical current is applied.

This process only takes less than a second and is non-invasive and then youre off, said Dr. Chan of Ohio State Wexner Medical Center. The chip does not stay with you, and the reprogramming of the cell starts.

That reprogramming turns skin cells into nearly any type of cell doctors might need to treat a patient a breakthrough technology in regenerative medicine.

For example, in a leg that is badly injured and lacks blood flow, doctors simply touch the chip to the leg and reprogram the skin to become functioning blood vessels.

And it will quickly shoot the DNA right into the cells, said Dr. James Lee of the Ohio State College of Engineering.

In many cases in seven days, you start seeing changes and these changes to our pleasant surprise persists, Dr. Sen said.

Within a week, there are active blood vessels and by the second week, the leg is saved.

It is important to note that the procedure has not yet been tested in humans. But after developing the concept, researchers were determined to test it in real life.

So we tried them on the mouse and put it on the skin, and you know what? It actually works, said Dr. James Lee of the Ohio State College of Engineering. It affects the entire tissue, not just the surface.

An image shows the mouses leg is injured, and vascular scans show there is little blood flow. But after one touch with the chip, in just three weeks, the blood flow was back and the injured leg was saved.

Our technology is not just limited to be used on the skin, Dr. Sen said. It can be used in other tissues within the body or outside the body, so on and so forth. So, skin is only one example.

In fact, in lab tests the chip even worked in the brain helping mice recover from strokes. In humans, it could allow doctors to grow brain cells on a persons skin under the guidance of their own immune system.

They could then harvest the cells and inject them into the brain to treat conditions such as Alzheimers disease and Parkinsons disease without any immune suppression drugs being necessary.

The electrical current actually opens up channels in the skin cells that allow the delivery of factors that are known to change the expression of certain genes in those cells. Better yet, the reprogramming doesnt have to be in a hospital setting because there is nothing invasive about it.

Read the rest here:
Microchip May Fix Damaged Cells And Organs, Scientists Say ... - CBS New York

Read More...

Okyanos Center for Regenerative Medicine to Hold Stem Cell Symposium in Freeport – Benzinga

Thursday, August 10th, 2017

First Annual Meeting Will Host Healthcare Administrators and Practitioners to Highlight Stem Cell Research Advances and Applications Through Expert Panel Discussions

Freeport, Grand Bahama (PRWEB) August 09, 2017

Okyanos Center for Regenerative Medicine has announced its First Annual Regenerative Medicine Symposium will take place at the Pelican Bay Hotel in Freeport, Grand Bahama on September 27, 2017. This daytime event is free to attend, however space is limited and pre-registration is required.

With oversight from the Ministry of Health's National Stem Cell Ethics Committee (NSCEC) and regulations laid out in the Stem Cell Research and Therapy Act passed in 2013, The Bahamas remains a leader in the global regenerative medicine community. Okyanos Center for Regenerative Medicine was the first cell therapy facility to meet the required standards and began treating patients in 2014.

Healthcare practitioners and administrators are encouraged to participate in the upcoming symposium which will feature specialist presentations, expert panel discussions and live Q&A sessions. The symposium will conclude in time for guests to attend the Okyanos-sponsored Grand Bahama Medical and Dental Association (GBMDA) welcome cocktail reception which will take place at 6:00pm on September 27th at the Pelican Bay.

"It is great to have this year's Grand Bahama Medical and Dental Association conference coordinated with the regenerative medicine symposium," said Dr. Vincent Burton who serves as Okyanos President and Chief Anesthesiologist as well as Vice President of the GBMDA. "The partnership we have forged should ensure an abundance of learning and networking opportunities for attendees."

Director of Research and Development Marc Penn, MD, PhD, FACC, will moderate the informative sessions and address the symposium to share an overview of Okyanos' planned research foci and strategic direction. "Through this annual meeting and others like it, we hope to encourage ongoing discussions which are critical to the development of the regenerative medicine industry both locally and internationally," said Dr. Penn.

To learn more and to register for Okyanos' First Annual Regenerative Medicine Symposium, please visit the Okyanos website.

ABOUT OKYANOS CENTER FOR REGENERATIVE MEDICINE (OH KEY AH NOS): Combining state-of-the art technologies delivered in a cell therapy center of excellence, Okyanos Center for Regenerative Medicine is a leading adult stem cell therapy provider located in Freeport, Grand Bahama. Okyanos was founded in 2011 and is licensed and accredited by the Bahamas' National Stem Cell Ethics Committee (NSCEC) under the Bahamas Stem Cell Therapy and Research Act to provide cell therapy to patients with chronic medical needs that, per scientific research, clinical trials and application, can be safely and potentially efficaciously treated with patients' own adipose-derived stem and regenerative cells. The literary name Okyanos, the Greek god of the river Okeanos, symbolizes restoration of blood flow. Learn more at http://www.okyanos.com.

For the original version on PRWeb visit: http://www.prweb.com/releases/2017/08/prweb14585069.htm

See the rest here:
Okyanos Center for Regenerative Medicine to Hold Stem Cell Symposium in Freeport - Benzinga

Read More...

Regenerative Medicine Market in the US – Forecasts, Segmentation, and Opportunity Assessment by Technavio – Business Wire (press release)

Friday, August 4th, 2017

LONDON--(BUSINESS WIRE)--According to the latest market study released by Technavio, the regenerative medicine market in the US is expected to grow at a CAGR of almost 24% during the forecast period.

This research report titled Regenerative Medicine Market in the US 2017-2021 provides an in-depth analysis of the market in terms of revenue and emerging market trends. This market research report also includes up to date analysis and forecasts for various market segments and all geographical regions.

The regenerative medicine market in the US is expected to grow at a rapid pace during the forecast period. The major factors that are driving the demand for regenerative products are increasing investments in R&D activities and the rising incidence of chronic diseases. Leading vendors have increased their R&D investments to develop innovative medical therapies, which is driving the overall growth of the market. M&A and strategic alliances among vendors will have a significant impact on the market growth.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

Technavios healthcare and life sciences research analysts categorize the regenerative medicine market in the US into the following segments by end-user. They are:

Looking for more information on this market? Request a free sample report

Technavios sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Hospitals

Hospitals are the key end users in the market, which form a partnership with regenerative medicine manufacturing companies to provide cell therapy and tissue scaffolds to improve patient care and treatment. The increasing number of wound treatment, craniomaxillofacial surgery, knee replacement cases, and soft tissue repair has increased the demand for cell therapy and tissue scaffolds in the market.

According to Srinivas Sashidhar, a lead orthopedics and medical devices research analyst from Technavio, Hospitals provide cell therapy in outpatient settings to reduce the cost burden on the patient. The Centers for Medicare and Medicaid Services provides reimbursement to the hospitals based on the Current Procedural Terminology code and the type of cell or tissue scaffold product. A minimal amount is paid to the physician who performs the procedure. Most of the hospitals have budget constraints and are required to reduce medical expenses. This has made many hospitals to avoid purchasing the high-cost regenerative medicines.

ASCs

There is an increased need for monitoring chronic conditions outside hospitals. The growing focus toward offering more consumer-friendly outpatient services and locations has increased the demand for ASCs. Individuals who have received vital signs monitoring in emergency rooms will step into urgent care centers. ASCs have a limited number of suppliers.

The government in the US focuses on reducing overall hospital costs. Governments pay low reimbursements in these centers compared with hospitals, which helps in making profits. In addition, these centers offer better patient care, and people can go through the same services offered in hospitals at a lower cost, which will lead to an increase in surgical procedures in these centers, adds Srinivas.

Regenerative medicine centers

Regenerative medicine centers are certified clinics that offer healthcare services to people. These centers have specialized departments for regenerative medicine, which offer care and treatment. For instance, the Regenerative Medicine Clinic at the Cedars-Sinai Heart Institute offers treatment and consultation for heart patients. For such patient pool, the clinic investigates the effect and efficiency of stem cell therapy.

Kansas Regenerative Medicine Center in the US provides stand-alone stem cell therapy. It offers autologous adipose-derived stem cell treatments. It contains multidisciplinary physicians to provide treatment to the patients. The skilled professionals conduct mini liposuction procedures to isolate and implant patients source of regenerative cells from the fat tissue.

The top vendors highlighted by Technavios research analysts in this report are:

Browse Related Reports:

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

More:
Regenerative Medicine Market in the US - Forecasts, Segmentation, and Opportunity Assessment by Technavio - Business Wire (press release)

Read More...

China Regenerative Medicine International Ltd (8158.HK) Reaches Active Mover List – Morgan Research

Friday, August 4th, 2017

Shares ofChina Regenerative Medicine International Ltd (8158.HK) is moving on volatility today-0.90% or -0.002 from the open.TheHKSE listed companysaw a recent bid of0.22 on1530000 volume.

Dedicated investors often strive hard to set themselves up for success. Finding long-lasting success in the stock market may not be an easy endeavor. The mindset of a short-term trader may differ greatly from that of a long-term investor. Investors often have to be prepared for many different situations. Obtaining the proper knowledge about stocks and the investing world is typically a main goal for active traders and investors. Once the investor is armed with knowledge, they may be able to see things that others cannot. This may involve staying up to date on various fundamentals, technicals, and macro-economic conditions.

Taking a deeper look into the technical levels ofChina Regenerative Medicine International Ltd (8158.HK), we can see thatthe Williams Percent Range or 14 day Williams %R currently sits at -50.00. The Williams %R oscillates in a range from 0 to -100. A reading between 0 and -20 would point to an overbought situation. A reading from -80 to -100 would signal an oversold situation. The Williams %R was developed by Larry Williams. This is a momentum indicator that is the inverse of the Fast Stochastic Oscillator.

China Regenerative Medicine International Ltd (8158.HK) currently has a 14-day Commodity Channel Index (CCI) of -15.72. Active investors may choose to use this technical indicator as a stock evaluation tool. Used as a coincident indicator, the CCI reading above +100 would reflect strong price action which may signal an uptrend. On the flip side, a reading below -100 may signal a downtrend reflecting weak price action. Using the CCI as a leading indicator, technical analysts may use a +100 reading as an overbought signal and a -100 reading as an oversold indicator, suggesting a trend reversal.

The RSI, or Relative Strength Index, is a widely used technical momentum indicator that compares price movement over time. The RSI was created by J. Welles Wilder who was striving to measure whether or not a stock was overbought or oversold. The RSI may be useful for spotting abnormal price activity and volatility. The RSI oscillates on a scale from 0 to 100. The normal reading of a stock will fall in the range of 30 to 70. A reading over 70 would indicate that the stock is overbought, and possibly overvalued. A reading under 30 may indicate that the stock is oversold, and possibly undervalued. After a recent check, China Regenerative Medicine International Ltds 14-day RSI is currently at 44.93, the 7-day stands at 46.99, and the 3-day is sitting at 44.24.

Currently, the 14-day ADX for China Regenerative Medicine International Ltd (8158.HK) is sitting at 22.53. Generally speaking, an ADX value from 0-25 would indicate an absent or weak trend. A value of 25-50 would support a strong trend. A value of 50-75 would identify a very strong trend, and a value of 75-100 would lead to an extremely strong trend. ADX is used to gauge trend strength but not trend direction. Traders often add the Plus Directional Indicator (+DI) and Minus Directional Indicator (-DI) to identify the direction of a trend.

Excerpt from:
China Regenerative Medicine International Ltd (8158.HK) Reaches Active Mover List - Morgan Research

Read More...

Regenerative Medicine Market in the US to Grow at a CAGR of 23.5 … – Business Wire (press release)

Tuesday, August 1st, 2017

DUBLIN--(BUSINESS WIRE)--The "Regenerative Medicine Market in the US 2017-2021" report has been added to Research and Markets' offering.

The Regenerative Medicine Market in the US to grow at a CAGR of 23.53% during the period 2017-2021.

The report, Regenerative Medicine Market in the US 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

The latest trend gaining momentum in the market is the increasing strategic alliances. Major vendors are entering into strategic alliances with other vendors for drug development and manufacturing. The trend is anticipated during the forecast period. Leading vendors in the market are undertaking M&A to strengthen their global position and to improve their commercial capabilities. Through increasing strategic alliances, many companies are receiving upfront and royalty payment, which encourages many small companies to involve into R&D and develop novel regenerative medicine products.

According to the report, one of the major drivers for this market is CVD and diabetes in young adult and aging population. CVD is a common disease in the older population; however, it is growing high among young adults owing to lifestyle and over-indulgement in junk foods. A combined study conducted by the Department of Clinical and Experimental Medicine, University of Florence; Department of Health Sciences, University of Milano-Bicocca; and Department of Cardiology, S. Luca Hospital, IRCCS Istituto Auxologico Italiano, Italy in 2015, found that uncontrolled blood pressure increases the risk of CVDs such as stroke and heart attack.

Key vendors

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Market landscape

PART 06: Pipeline portfolio

PART 07: Market segmentation by product

PART 08: Market segmentation by application

PART 09: Market segmentation by end-user

PART 10: Decision framework

PART 11: Drivers and challenges

PART 12: Market trends

PART 13: Vendor landscape

PART 14: Key vendor analysis

For more information about this report visit https://www.researchandmarkets.com/research/8dnt7z/regenerative

See the original post here:
Regenerative Medicine Market in the US to Grow at a CAGR of 23.5 ... - Business Wire (press release)

Read More...

Regenerative Medicine – AABB

Tuesday, August 1st, 2017

Regenerative medicine may be defined as the process of replacing or "regenerating" human cells, tissues or organs to restore or establish normal function. This field holds the promise of regenerating damaged tissues and organs in the body by replacing damaged tissue or by stimulating the body's own repair mechanisms to heal tissues or organs. Regenerative medicine also may enable scientists to grow tissues and organs in the laboratory and safely implant them when the body is unable to heal itself. Current estimates indicate that approximately one in three Americans could potentially benefit from regenerative medicine.

Regenerative Medicine refers to a group of biomedical approaches to clinical therapies that may involve the use of stem cells. Examples include cell therapies (the injection of stem cells or progenitor cells); immunomodulation therapy (regeneration by biologically active molecules administered alone or as secretions by infused cells); and tissue engineering (transplantation of laboratory grown organs and tissues). While covering a broad range of applications, in practice the latter term is closely associated with applications that repair or replace portions of or whole tissues (i.e., bone, cartilage, blood vessels, bladder, skin). Often, the tissues involved require certain mechanical and structural properties for proper functioning. The term has also been applied to efforts to perform specific biochemical functions using cells within an artificially-created support system (e.g., artificial pancreas or liver).

Cord blood stem cells are being explored in several applications including Type 1 diabetes to determine if the cells can slow the loss of insulin production in children; cardiovascular repair to observe whether cells selectively migrate to injured cardiac tissue, improve function and blood flow at the site of injury and improve overall heart function; and central nervous system applications to assess whether cells migrate to the area of brain injury alleviating mobility related symptoms, and repair damaged brain tissue (such as that experienced with cerebral palsy). Cord blood stem cells likely will be an important resource as medicine advances toward harnessing the body's own cells for treatment. Because a person's own (autologous) stem cells can be infused back into that individual without being rejected by the body's immune system, autologous cord blood stem cells have become an increasingly important focus of regenerative medicine research.

Regenerative medicine has made its way into clinical practice with the use of materials that are able to assist in the healing process by releasing growth factors and cytokines back into the damaged tissue (e.g., (chronic) wound healing). As additional applications are researched, the fields of regenerative medicine and cellular therapies will continue to merge and expand, potentially treating many disease conditions and improving health for a variety of diseases and health conditions.

Read the original here:
Regenerative Medicine - AABB

Read More...

With New Biotech Institute, Manchester Aims to Be Hub for … – Nhpr – New Hampshire Public Radio

Tuesday, August 1st, 2017

Dean Kamen brought the world the Segway and helped to transform New Hampshire's Millyard from a hollowed-out manufacturing strip to a growing tech hub. Now, he's setting his sights on making Manchester a hub for a whole new field of medicine.

It sounds like the kind of stuff that at one time was relegated to science fiction. An organ, grown from scratch, to replace one at risk for renal failure. A new, fully functioning limb for a soldier who lost his to combat.

But that's exactly the vision at the heart of the Advanced Regenerative Manufacturing Institute, or BioFabUSA -- a multimillion-dollar partnership led by Kamen and the Department of Defenseto come up with new approaches to biotechnology.

ARMI (pronounced like "army") launched primarily to help soldiers, but Kamen sees wide-reaching potential for patients across the board.

"If you had a choice of, you could treat my end-stage renal failure by sending me to a dialysis center three days a week for the rest of my life, or you can cure it, by giving me a replacement organ, which would you prefer? And if you could prevent the problem in the first place, which would you prefer?" Kamen said at an ARMI launch event in Manchester on Friday. "So, ironically this is one of those rare places where thetechnologythat we're developing is one that is going to give you a betteroutcome, but it also lowers the cost."

Kamen nabbed a former top official at the FDA to get the institute up and running, and he said he's secured more than $200 million in funding -- in addition to the $80 million the Department of Defense put up to launch the effort.

"We told the Department of Defense within five years, we will have products that are being placed in or on people to cure conditions that are a result of what's going on in this place," Kamen said. "I'd like to think some of them are sooner than that, but that's our goal."

And the inventor's not the only one excited about it.

"I love it," said Gov. Chris Sununu, one of several local dignitaries on hand for the launch. "Look, anything I can do to attract more geeks to New Hampshire, being a former geek myself."

Sununu was joined at the launch event by Sens. Maggie Hassan and Jeanne Shaheen, former Gov. John Lynch, former Sen. Kelly Ayotte and a number of other top names in the state's political, business and tech scenes -- the takeaway being, policymakers are seeing this as a big deal, and a big get for the Granite State.

More here:
With New Biotech Institute, Manchester Aims to Be Hub for ... - Nhpr - New Hampshire Public Radio

Read More...

The Big Deal About Stem Cell Therapies and Regenerative Medicine – PR Newswire (press release)

Tuesday, August 1st, 2017

However, when looking at this great promise in terms of return on investment, let us be completely honest, most early stage stem cell investors have lost their shirts. We are now more than twenty years removed from the earliest commercial stem cell companies that were founded in the late 1980's, went public in the late 1990's and who were once seen as an exciting investment opportunity, but ended up being a huge disappointment.

So, should investors still be interested in regenerative medicine? After all, stem cells have largely produced failures and unregulated stem cell clinics marketing unproven therapies are taking over. The answer is a resounding yes, but the dot-com like era of regenerative medicine, which led investors to pour money into anything and anyone marketing a cell therapy is over. Investors will need to look at companies solving issues with stem cells or those taking a completely new approach.

One company that is looking to address many of the issues with stem cell therapies, as well as developing another approach to regenerative medicine is Endonovo Therapeutics, Inc. (OTCQB: ENDV). On the stem cell front, ENDV is using its Time Varying Electromagnetic Fields (TVEMF) technology, originally developed at the National Aeronautics and Space Administration (NASA) to expand and activate stem cells to produce more biologically potent cell therapies. However, more importantly, ENDV is developing a non-invasive medical device that would render many of the cell therapies currently under development obsolete. These devices, called Electroceuticals, harness the electrical signals that our cells and nerves use to control the immune and regenerative response to treat inflammatory and degenerative diseases. ENDV is developing this exciting technology for treating and preventing heart failure following a heart attack, to treat chronic kidney disease, peripheral artery disease and non-alcoholic steatohepatitis (NASH).

Another small biotech company like ENDV working on electric treatments for diseases is Pulse Biosciences (NASDAQ: PLSE), whose Nano-Pulse Stimulation (NPS) technology uses nano second electric pulses to illicit an immune response for the treatment of cancer. PLSE recently announced the treatment of its first patient in a study to evaluate the safety and efficacy of its novel NPS technology for seborrheic keratosis (SK) lesions. SK is one of the most common types of skin lesions, affecting more than 80 million patients in the United States. Additionally, PLSE announced that it will host its quarterly investor conference call on July 27, 2017, at 1:30 p.m. PDT / 4:30 p.m. EDT. The company will provide an update on the clinical advancement of the PulseTx[TM] System, including progress of the clinical study evaluating NPS for the treatment of seborrheic keratosis (SK), as well as the status of the 510(k) submission from earlier this year.

Another company seeking to address past pitfalls of stem cell therapies is Pluristem Therapeutics, Inc. (NASDAQ: PSTI) is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. Pluristem's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. This process allows the cells to be expanded rapidly while remaining healthy and potent cells that can secrete therapeutic biomolecules. The Company's PLX products are administered using a standard needle and syringe. PSTI recently announced that Austria's regulatory health agency, the Austrian Agency for Health and Food Safety (AGES), had cleared Pluristem to begin enrollment in Austria for its pivotal Phase III trial of PLX-PAD cells to treat critical limb ischemia.

In other stem cell news:

Cytori Therapeutics, Inc. (NASDAQ: CYTX) recently announced that its STAR study assessing its Habeo Cell Therapy for the treatment of Scleroderma had failed to meet its primary endpoint at week 24 nor any of its secondary endpoints at week 24 or week 48. On the other hand, CYTX stated that there were 'clinically meaningful' improvements in both the primary and secondary endpoints of both hand function and scleroderma-associated functional disability compared to placebo in a subgroup of patients with diffuse cutaneous scleroderma, a more severe form of the disease. The company has stated that it will continue it analysis of the data before determining its next steps.

Capricor Therapeutics, Inc. (NASDAQ: CAPR) a biotechnology company developing biological therapies for Duchenne muscular dystrophy and other rare diseases, following news that Janssen Biotech, Inc. had decided not to exercise its option to exclusively license Capricor's lead candidate CAP-1002 for the development and commercialization in the field of cardiology, announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to CAP-1002, Capricor's development candidate for the treatment of Duchenne muscular dystrophy, a debilitating genetic disorder characterized by progressive weakness and chronic inflammation of skeletal, heart, and respiratory muscles. The Rare Pediatric Disease Designation, as well as the Orphan Drug Designation previously granted to CAP-1002 by the FDA, covers the broad treatment of DMD. Upon receiving market approval for CAP-1002 by the FDA, Capricor would be eligible to receive a Priority Review Voucher.

Microcap Speculators

Email: info@microcapspecualtors.com

Phone: +1-702-720-6310

Website: http://microcapspeculators.com/

DISCLAIMER: Microcap Speculators (MS) is the source of the content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MS or any company mentioned herein. The commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

MS Disclosure: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For Full Legal Disclaimer Please use this link:http://microcapspeculators.com/disclaimer/

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements.

Media ContactFN Media Group, LLCeditor@financialnewsmedia.com+1-(954)345-0611

SOURCE Microcapspeculators.com

Link:
The Big Deal About Stem Cell Therapies and Regenerative Medicine - PR Newswire (press release)

Read More...

Regenerative medicine startup Rodeo Therapeutics raises $5.9M for … – GeekWire

Tuesday, August 1st, 2017

Dr. Sanford Markowitz, founder of Rodeo Therapeutics. (Case Western Reserve University Photo)

If you could write a medical wish-list of futuristic technologies, regenerating tissue would be pretty high up there. It could do things like treat a variety of inflammatory conditions and even help cancer patients regrow healthy cells.

A new Seattle-based biotech startup, Rodeo Therapeutics, is hoping its technology can make tissue regeneration a reality, and it has just raised a $5.9 million Series A round from Seattle-based biotech fund Accelerator Corporationto make it happen.

The general idea is simple: Rodeo is hoping to use small-molecule therapies a category most drugs fall into that stimulate the bodys natural regeneration process, like when a skinned knee heals.

Its first focus is to develop a treatmentfor inflammatory bowel disease and one that can help cancer patients cells grow quickly following stem cell transplants.

But those goals are just the beginning.

The ability to stimulate the bodys natural processes for tissue regeneration and repair has broad therapeutic potential in disease settings such as ulcerative colitis and in hemopoietic recovery following bone marrow transplantation,said Rodeo Therapeutics founder and cancer researcher Dr.Sanford Markowitz. Rodeo Therapeutics is focused on developing small-molecule therapies that stimulate these processes and enable new approaches to address serious medical conditions that today have a substantial unmet medical need.

The company is currently working on drugs that inhibit an enzyme called 15-PGDH, which has been shown to speed up regenerative processes.

The startup was founded by Markowitz and Dr. Stanton Gerson, researchers at Case Western University, along with Dr.Joseph Ready, a researcher at the University of Texas Southwestern Medical Center.

Its technology is based on their work. Markowitz is an expert in gastrointestinal cancers, where inflammation can cause serious problems; Dr. Gerson specializes in stem cell and genetic research along with gene therapies and cancer drug development; and Dr. Ready works in regenerative medicine and cancer, specifically synthetic and medicinal chemistry.

The startups corporate office is currently in Accelerator Corporations facilities in Seattle, with its founders in Dallas and Cleveland. Rodeos early operations will be overseen by Accelerator, and the funds CEO Thong Le is currently servingas Rodeos CEO.

Visit link:
Regenerative medicine startup Rodeo Therapeutics raises $5.9M for ... - GeekWire

Read More...

Scitech | My experience with regenerative medicine – The McGill Daily (blog)

Tuesday, August 1st, 2017

Content warning: drug addiction, mental illness, disability

I remember the hot summer afternoon in July 2007 when I injured my back. It was a day that would change my life. I was 18, and taking part in a military program to qualify as a professional infantry soldier in the Canadian Armed Forces. My injuries all started during the first phase of a 10-kilometer walk, while carrying a 40-pound rucksack. As training progressed, I began to feel an odd sense of discomfort in my lower back. After I returned to my dorm later that day and unstrapped the rucksack, I felt a sharp pain going down from my lower back to my leg. Before bed, I took a couple of aspirin pills and washed them down with gin. The next morning, the pain had partly subsided, but the discomfort and feeling that something was wrong with my back stuck with me for days after. Weeks later, during another military exercise with a rucksack, I hurt my back so severely that I needed to see the nurse. At the time, I did not know that the following ten years would be comprised of pain from the moment I wake up to the moment I go to bed. This was the beginning of my struggle with chronic pain. Since then, I have been trying to find a way to cure my back, leading me to try regenerative medicine treatments such as Platelet Rich Plasma (PRP) and stem cells.

For the past ten years, Ive seen chiropractors, physiotherapists, psychiatrists, rheumatologists, osteopaths and virtually every health professional to treat my injury. I tried decompression therapy, kinesiotherapy, swimming, physiotherapy, non-steroidal anti-inflammatories drugs (NSAIDs), steroid injections, oral steroids, acupuncture, Chinese therapeutic massage, and praying but nothing worked. After various treatments fell through, what made the journey of searching for a cure even more difficult was the general apathy from medical doctors in Canada. Some medical specialists thought that the extent of my injury did not match the severity of the pain, therefore, my pain was merely an illusion. They dismissed my medical condition and recommended that I swim more or become more physically active. While some doctors believed me, they still didnt know how to help me. For almost eight years, I fought an uphill battle trying to convince medical professionals that I was worth their time and that I needed help. This struggle profoundly impacted my mental health.

I was stuck in a prison of pain from which I could not escape. 6 years after the injury, the pain has grown into a disability. There were days when I could barely walk or sit down for more than a few minutes. At times, my life felt like a nightmare. Activities most people take for granted, such as showering or cleaning a room, quickly became strenuous for me. Chronic pain also started impacting other areas of my life; my studies, my work, and even my relationships. I almost failed my first year of law school because of chronic pain. It made me start drinking again, and it put me into a state where I was consumed by narcotics and depression. After years of feeling despair and being unable to find an effective treatment through Canadas healthcare system, I started looking into private medical practice in the US in 2015.

Regenokine

In January of 2016, I went to New York, where I had my first experience with regenerative medicine. I went to NY Spine Medicine to get the same treatment that Kobe Bryant had received for his knees a few years back in 2013 Regenokine.

Regenokine is an anti-inflammatory serum made from the patients blood to suppress back and joint pain. The serum is made by taking some of the patients blood, heating it, and incubating it with zinc etched with glass beads. It is believed that the serum becomes rich in Interleukin 1 Receptor Antagonist Protein (IRAP), which is a natural anti-inflammatory. According to the medical doctors from NY Spine Clinic, once the serum is injected at the site of injury, it reduces the inflammation and speeds up the bodys own healing mechanism. Its as if you had a strong dose of Tylenol directly injected in an ankle or your back.

The treatment is recent; it was first developed by a doctor in Dusseldorf, Germany around 15 years ago. NY Spine Medicine is one of the institutes in the US that offer this treatment, and the cost of it is obscenely high. The treatment cost me around 17,000 US dollars for four consecutive days of injections.

I had around about 600 ml of blood taken out, and in the next four days had the serum re-injected into my lower back: facet joints, epidural space, and all around the lower spine. At the beginning of my treatment, the pain was at an all-time high and I could barely sit for more than 5 minutes. Every day of injections resulted in more and more of the pain dissipating. On the last day, before my last round of injections, I woke up pain-free for the first time in years. Shaken by the relief and emotions, I started crying I could not believe how good it felt to be free of pain. It was a miracle, but a short-lived one: the pain-relieving effects of the treatment only lasted for two months before my back started hurting once again.

Platelet Rich Plasma (PRP)

Few months passed after the Regenokine treatment and the memory of being pain-free started to fade away, but I still had hope. I kept dreaming of finding another treatment that could heal me completely. I began researching alternative treatments and eventually found the Centeno-Schultz Clinic in Colorado; they used Platelet Rich Plasma (PRP) and stem cells to treat back pain.

My first treatment at the clinic was an injection of PRP in my lower back, neck, and hips. PRP is very similar to Regenokine in that it is an autologous serum it is made with the patients blood. The difference is that while Regenokine works as an anti-inflammatory, the process by which PRP works is inflammatory. The doctor who treated me explained that PRP forces the body into a super inflammatory state, and as the inflammation subsides, it accelerates the reconstruction of ligaments and other tissues, which would in turn ease the pain. I had PRP injected into my sacroiliac joint, my lower back epidural space, and everywhere around my facet joints in my neck and back. In the first few days after the treatment, my pain levels flared up. However, in the next few weeks, the pain went down progressively, and I regained some degree of mobility. The most dramatic change was in my neck: the pain level went from a high 6-7 out of 10 to nearly a 1 within a few days. After a month, my lower back and hips felt as if they were almost healed. Although the effect of the treatment was not as dramatic as Regenokine, it lasted for a few months. I went from limping and barely being able to function to being able to play sports and go to class again. Unfortunately, like Regenokine, the healing effects of PRP were temporary. The treatment cost me around 10,000 US dollars.

Stem cells

Stem cell treatment was my last hope with regards to regenerative medicine. On May 28, I flew to the Cayman Islands for my stem cell treatment with a clinic affiliated with Centeno-Schultz Clinic. Like PRP and Regenokine, the stem cell treatment was autologous. I had three huge syringes of bone marrow aspirated from my hip bone. Mesenchymal stem cells were extracted from the bone marrow and cultivated to grow. Mesenchymal stem cells are multipotent stem cells that can transform into different types of cells depending on the situation. In my case, the stem cells were injected inside of my L5-S1 intervertebral disc with the hope that they would transform into disc tissue and help my lumbar spine heal.

The first few days after the operation, the pain was almost unbearable without oxycodone, a narcotic. It was nearly impossible to walk, bend forward, or even dress myself. The doctor informed me that I would see my pain flare up in the following four weeks, but in time, I would regain range of motion. I was also told that eventually my body is likely to be healed a hundred percent. The results are promising thus far. It has been almost three weeks since the treatment, and I have already gained back mobility and functionality. There is something changing in my back. I used to be in pain from morning to night, now after a good night of sleep, I usually wake up free from pain. In the morning, there is slight discomfort in my hip and lower back area, but no pain until I move too much or sit for too long. It takes four to six months to evaluate the full result, which seem hopeful. The stem cell treatment for my lower back and hip cost 29,000 US dollars.

Regenerative medicine does work amazingly well, but its drawback is in its exorbitant price and inaccessibility in Canada. I believe regenerative treatment is the future of medicine, and hope that the three treatments are made available in Canada as soon as possible. In total, I spent over 70,000 Canadian dollars just for my three treatments. No one should have to pay that much to live free of pain. Health is crucial to happiness, and it should never be the privilege to the only few who can afford expensive medical trips abroad.

An earlier version of this article stated thatNY Spine Medicine is the only institute in the US that offers Regenokine. In fact, there are other institutes in the US that offer the treatment. The Daily regrets the error.

Sami Ellaia is a 3L student at the Faculty of Law. To reach him, please contact sami.ellaia@mail.mcgill.ca.

The rest is here:
Scitech | My experience with regenerative medicine - The McGill Daily (blog)

Read More...

Mayo Confirms First Tenants at Discovery Square Project – Twin Cities Business Magazine

Wednesday, July 12th, 2017

Mayo Clinic has confirmed that researchers from its regenerative medicine and genomics/individualized medicine programs will be among the first tenants of the initial Discovery Square medical office building in downtown Rochester.Last June, Mayo Business Development Chairman Jim Rogers told TCB that medical specialists from the clinics three transformational centers were among the likeliest early occupants of Discovery Squares first-phase building, which is seen as a key component in jump-starting Mayos ambitious Destination Medical Center effort.The trio of transformational centers include Center for Individualized Medicine, theCenter for Regenerative Medicine and theMayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery.Development plans for the 60,000-square-foot Discovery Square Phase I building were announced in April by Mortenson Construction, which will build and own the structure with Mayo signed on as lead tenant. The goal of Discovery Square is to place Mayo researchers into close collaboration with biotech and medtech companies seeking to commercialize their innovations, thus hopefully establishing Rochester as one of the countrys premier bio-business clusters while also getting new devices and therapies out to patients sooner.The clinic recently officially revealed that researchers concentrating in regenerative medicine and individualized medicine/genomicsalong with a new Mayo/industry collaborative biotech incubator spacewill indeed be among those who will be located within the 30,000 square feet leased by Mayo in the DS-1 building when It opens in 2019.Our research presence in Discovery Square will serve as a catalyst for ideas and projects that transform medicine and accelerate the discovery, translation and application of life-changing therapies and technologies so our patients receive exactly the care they need when its needed,Gregory Gores, M.D., Mayos executive dean of research, said in the announcement.Gores described the three aspects of Mayos presence in the DS-1 Building:Biotech incubator: Calling this space a true science incubator, Gores said its work will concentrate on developing innovative ways to apply technologies to be initially focused on ultrasound. Its designed to be expanded into other modalities and engineering technologies as needed. The space will enable interaction with industry partners to jointly enhance and develop new uses for biomedical devices.Advanced manufacturing of regenerative products: Mayo said this area will focus on creating products that can be used for therapeutic treatment, particularly products for regenerative therapies. It will be set up to enable the development and potentially the production of these new therapies.Genomics-based diagnostics center: The clinic will use this space to collaborate with outside groups on new medical tests that can better diagnose disease, specifically using genomics and other tools to focus on conditions that dont yet have clinical diagnostic tests and develop better tests for those that do.Mortenson says groundbreaking on the DS-1 project is planned for late this year with a target completion date in 2019. Designed by Minneapolis-based RSP Architects, the facility will be built on what is now a Mayo employee parking lot at the corner of 4th Street S.W. and 2nd Avenue S.W., in the 16-block Discovery Square sub-district of the larger Destination Medical Center planning zone.It features a unique, integrated design with flexible, open workspaces allowing Mayo researchers to adapt to ever-changing needs in the life science industry, while centralized common spaces within the building is designed to promote interaction among Mayo scientists and commercial collaborators also leasing space there.The 20-year DMC vision calls for an eventual office space build-out of 2 million square feet within the Discovery Square sub-district.

Original post:
Mayo Confirms First Tenants at Discovery Square Project - Twin Cities Business Magazine

Read More...

Page 38«..1020..37383940..5060..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick